OncoMatch/Clinical Trials/NCT02925234
The Drug Rediscovery Protocol (DRUP Trial)
Is NCT02925234 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for cancer.
Treatment: Panitumumab · Olaparib · Dabrafenib · Nilotinib · Trametinib · Erlotinib · Trastuzumab and Pertuzumab (combination treatment) · Vemurafenib and Cobimetinib (combination treatment) · Vismodegib · Regorafenib · Nivolumab · Afatinib · Dabrafenib and trametinib · Ribociclib · Lenvatinib · Pembrolizumab · Durvalumab · Rucaparib · Axitinib · Palbociclib · Crizotinib · Sunitinib · Cabozantinib · Abemaciclib · Alectinib · Atezolizumab and Bevacizumab · Ipilimumab and nivolumab · Entrectinib · Talazoparib · Dacomitinib · Lorlatinib · Erdafitinib · Alpelisib · Niraparib · Pemigatinib · Selpercatinib · Tepotinib — This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs\* prescribed for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic or protein expression test. The study also aims to simplify patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing on tumor biopsies for biomarker analyses. Eligible patients have an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma for which standard treatment options are no longer available and acceptable performance status and organ function. A genomic or protein expression test must have been performed on the tumor and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Results from the molecular profiling test will be used to determine an appropriate drug(s) from among those available in the protocol. The choice of drug will be supported by a list of potential profiles, a molecular tumor board, a knowledge library and by study coordinators for review and approval of the match. The protocol-specified treatment will be administered to the patient once any drug-specific eligibility criteria are confirmed and a fresh pre-treatment biopsy is performed for future genetic studies. All patients who receive treatment with a drug available in the protocol will be followed for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment. In addition, treatment related toxicity will be evaluated.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard anti-cancer treatment
progression according to RECIST-criteria after standard anti-cancer treatment or for whom no such treatment is available or indicated
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^9/l; Hemoglobin > 5.6 mmol/l; Platelets > 75 x 10^9/l
Kidney function
Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
Liver function
Total bilirubin < 2 x ULN; AST (SGOT) and ALT (SGPT) < 2.5 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
Cardiac function
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible. Patients with known left ventricular ejection fraction (LVEF) < 40% are not eligible. Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible.
Patients must have acceptable organ function as defined below...specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify